Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 5/20 | 0.42 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10276018 | 0.99 | MAP2K1 (0.50) | MAP2K1SLC6A4SLC6A2SLC6A3HTR2A | |
| SCHEMBL28762473 | 0.90 | MAP2K1 (0.51) | MAP2K1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2561940 | 0.89 | SLC6A4 (0.44) | MAP2K1SLC6A4SLC6A2SLC6A3SCD | |
| Hydrochloric Acid SCHEMBL1230448 | 0.88 | SLC6A4 (0.43) | MAP2K1SLC6A4SLC6A2SLC6A3SCD | |
| SCHEMBL26014127 | 0.87 | MAP2K1 (0.51) | MAP2K1SLC6A4SLC6A2SLC6A3KDM1A | |
| SCHEMBL31071584 | 0.82 | MGLL (0.48) | MAP2K1SLC6A4SLC6A2KDM1AMAOB | |
| SCHEMBL13594955 | 0.80 | MAP2K1 (0.57) | MAP2K1SLC6A4SLC6A2SLC6A3KDM1A | |
| SCHEMBL21984967 | 0.79 | MRGPRX4 (0.47) | SLC6A4HTR2CHTR2B | |
| SCHEMBL3444230 | 0.78 | SLC6A2 (0.57) | SLC6A4SLC6A2SLC6A3KDM1AMAOB | |
| SCHEMBL3443767 | 0.78 | SLC6A2 (0.57) | SLC6A4SLC6A2SLC6A3KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462121-B1 | DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PF MEDICAMENT (FR) | 2015-02-18 | — | — | EP | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011015629-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | SCD, SCD5, CYP2S1 | MAP2K1 1913/4885SLC6A4 4102/4885SLC6A2 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.